Spine gurus K2M, Inc. have announced the promotion of Gianluca Iasci, formerly K2M’s Senior Vice President for International Sales, to the position of Executive Vice President, Global Sales.
Did the FDA kill CoAxia using the new de novo process? Despite reducing mortality rates in patients 2 to 1 over standard of care, the FDA pushed CoAxia into the new de novo process. In retrospect, it also killed the company. Attorney Mark DuVal, is warning clients to beware the de novo process lest it devours you.